Biotech Values

[dav1234]

More on Forest Laboratories (FRX -5%) FQ3: swings to net loss of $153.6M from profit of $278.4M, with earnings hurt by the expiration of Lexapro's patent in March 2012 and upfront licensing payments of $76M. Expects FY 2013 EPS at lower end of forecast of $0.45-$0.60 vs consensus of $0.25 - which looks to be a substantial discrepancy - and revenue of $3.1-$3.2B vs $3.15B.